Inflammatory mediators and pro-inflammatory cytokine signaling

Inflammatory mediators and pro-inflammatory cytokine signaling represent a broad biological framework rather than a single molecular entity. This system involves a diverse array of secreted proteins, such as Tumor Necrosis Factor (TNF), Interleukins (IL-1, IL-6, IL-17), and Interferons, which act as primary messengers in the immune system (StatPearls, 2023). Upon binding to their cognate receptors, these cytokines activate complex intracellular pathways, most notably the JAK-STAT and NF-κB cascades, which drive the transcription of genes essential for host defense and tissue repair (Nature Reviews Immunology, 2018). However, chronic or excessive activation of these pathways is a primary driver of autoimmune and autoinflammatory pathologies, leading to tissue destruction and systemic inflammation. Pharmacological modulation of this signaling network is a cornerstone of modern rheumatology and gastroenterology, utilizing biologics and small molecules to dampen the overactive immune response. Because these pathways are integral to normal immune surveillance, therapeutic inhibition requires a careful balance to avoid severe secondary infections or impaired wound healing (Frontiers in Pharmacology, 2021).

Other names

Cytokine signaling pathwayPro-inflammatory cascadeInflammatory signaling networkCytokine-mediated signaling

Drugs targeting this pathway function by neutralizing circulating pro-inflammatory ligands, competitively inhibiting cell-surface receptors, or blocking intracellular signaling enzymes such as Janus kinases to prevent gene transcription of inflammatory mediators (Nature Reviews Drug Discovery, 2012).